cas 19748-66-4|| where to buy 1-(3-HYDROXYPROPYL)-PYRROLIDINE

Nom du produit:1-(3-HYDROXYPROPYL)-PYRROLIDINE

IUPAC Name:3-(pyrrolidin-1-yl)propan-1-ol

Unité d'emballage	Stock disponible	Prix($)
CM101545-10g	in stock	ŗŗ
CM101545-25g	in stock	ǪƥŹ
CM101545-100g	in stock	ĲŗĲ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 19748-66-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:19748-66-4; Formule moléculaire:C7H15NO; Point de fusion:-; Code SMILES:OCCCN1CCCC1; Densité:

: Numéro de catalogue:CM101545; Poids moléculaire:129.2; Point d'ébullition:216.9°C at 760 mmHg; N° Mdl:MFCD01687769; Stockage:Store at 2-8°C.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: IDRX-42; IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.